Search research articles
Contact Us
Filters
Showing results (41-50 of 65) with videos related to
Page
of 7
Sort By:
American Journal of Hematology
|
July 21, 2021
Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation
Omer Jamy, Raquel Innis-Shelton, Susan Bal, et al.
Journal of Geriatric Oncology
|
December 20, 2021
Pre-treatment neutrophil to lymphocyte ratio as a biomarker of frailty and predictor of survival among older adults with multiple myeloma
Smith Giri, Sumit Dahal, Susan Bal, et al.
Blood
|
January 27, 2026
Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy
Susan Bal, Gayathri Ravi, Binod Dhakal, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
April 1, 2024
Low skeletal muscle mass and treatment outcomes among adults with haematologic malignancies: A systematic review and meta-analysis
Nadia M Anabtawi, Monica Sai Pasala, Alyssa A Grimshaw, et al.
Journal of Geriatric Oncology
|
September 6, 2024
Evaluating concordance between International Myeloma Working Group (IMWG) frailty score and simplified frailty scale among older adults with multiple myeloma
Andrew Gahagan, Supriya Maheshwari, Sunil Rangarajan, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 2, 2025
Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma
Ajai Chari, Susan Bal, Sikander Ailawadhi, et al.
Ejhaem
|
August 21, 2023
Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation, and measurable residual disease-response-adapted treatment cessation
Rebecca W Silbermann, Timothy Martin Schmidt, Susan Bal, et al.
British Journal of Haematology
|
February 16, 2026
Validation of the 2025 IMS/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant
Priyanka Venkatesh, Gayathri Ravi, Binod Dhakal, et al.
Leukemia
|
November 21, 2021
Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies
Susan Bal, Ehsan Malek, Ankit Kansagra, et al.
The Lancet. Haematology
|
September 30, 2023
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial
Luciano J Costa, Saurabh Chhabra, Eva Medvedova, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 65) with videos related to
Sort By:
Page
of 7
American Journal of Hematology
|
July 21, 2021
Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantation
Omer Jamy, Raquel Innis-Shelton, Susan Bal, et al.
Journal of Geriatric Oncology
|
December 20, 2021
Pre-treatment neutrophil to lymphocyte ratio as a biomarker of frailty and predictor of survival among older adults with multiple myeloma
Smith Giri, Sumit Dahal, Susan Bal, et al.
Blood
|
January 27, 2026
Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy
Susan Bal, Gayathri Ravi, Binod Dhakal, et al.
Journal of Cachexia, Sarcopenia and Muscle
|
April 1, 2024
Low skeletal muscle mass and treatment outcomes among adults with haematologic malignancies: A systematic review and meta-analysis
Nadia M Anabtawi, Monica Sai Pasala, Alyssa A Grimshaw, et al.
Journal of Geriatric Oncology
|
September 6, 2024
Evaluating concordance between International Myeloma Working Group (IMWG) frailty score and simplified frailty scale among older adults with multiple myeloma
Andrew Gahagan, Supriya Maheshwari, Sunil Rangarajan, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
April 2, 2025
Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma
Ajai Chari, Susan Bal, Sikander Ailawadhi, et al.
Ejhaem
|
August 21, 2023
Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd), autologous hematopoietic cell transplantation, and measurable residual disease-response-adapted treatment cessation
Rebecca W Silbermann, Timothy Martin Schmidt, Susan Bal, et al.
British Journal of Haematology
|
February 16, 2026
Validation of the 2025 IMS/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant
Priyanka Venkatesh, Gayathri Ravi, Binod Dhakal, et al.
Leukemia
|
November 21, 2021
Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies
Susan Bal, Ehsan Malek, Ankit Kansagra, et al.
The Lancet. Haematology
|
September 30, 2023
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial
Luciano J Costa, Saurabh Chhabra, Eva Medvedova, et al.
Page
of 7